Quick Answer
BioAtla, Inc. reported Net Income of -$59.61 million for fiscal year 2025.
BioAtla, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$59.61M +14.6% |
-$69.78M +43.5% |
-$123.46M -15.9% |
-$106.48M -11.6% |
-$95.40M -166.1% |
-$35.85M -20.1% |
| Diluted EPS | -$1.01 +29.9% |
-$1.44 +44.2% |
-$2.58 +5.8% |
-$2.74 +0.7% |
-$2.76 | — |
| Total Assets | $13.83M -73.6% |
$52.42M -56.2% |
$119.66M -47.0% |
$225.74M -11.3% |
$254.42M +3.9% |
$244.94M |
| Cash and Equivalents | $7.12M -85.5% |
$49.05M -56.0% |
$111.47M -48.3% |
$215.51M -12.0% |
$244.98M +2.7% |
$238.60M +6341.8% |
| Stockholders Equity | -$36.19M -353.7% |
$14.27M -79.8% |
$70.67M -60.8% |
$180.34M -14.5% |
$210.82M +0.4% |
$209.97M +474.9% |
| R&D Expense | $43.57M -30.9% |
$63.09M -39.2% |
$103.73M +30.7% |
$79.35M +36.2% |
$58.27M +192.3% |
$19.93M -23.1% |
| Operating Income | -$59.30M +19.8% |
-$73.94M +43.0% |
-$129.69M -19.9% |
-$108.14M -12.1% |
-$96.44M -220.4% |
-$30.10M -6.5% |
| Shares Outstanding | 63.46M +9.2% |
58.10M +20.8% |
48.08M +3.8% |
46.34M +29.4% |
35.80M +11.3% |
32.17M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$15.78M | -49.0% | +15.7% |
| Diluted EPS | September 30, 2025 | -$0.27 | -22.7% | +15.6% |
| Total Assets | September 30, 2025 | $15.91M | -74.4% | -41.4% |
| Cash and Equivalents | September 30, 2025 | $8.32M | -85.3% | -54.3% |
| Stockholders Equity | September 30, 2025 | -$31.24M | -236.0% | -86.5% |
| R&D Expense | September 30, 2025 | $9.54M | -41.8% | -30.3% |
| Operating Income | September 30, 2025 | -$13.79M | -22.4% | +26.1% |
| Shares Outstanding | September 30, 2025 | 58.79M | +21.6% | +0.1% |
- BioAtla, Inc. reported Net Income of -$59.61 million for fiscal year 2025.
- BioAtla, Inc. showed an increase of +14.6% in Net Income compared to the prior fiscal year.
- BioAtla, Inc. reported Diluted EPS of $1.01 per share (loss) for fiscal year 2025.
- BioAtla, Inc. showed an increase of +29.9% in Diluted EPS compared to the prior fiscal year.
- BioAtla, Inc. reported Total Assets of $13.83 million for fiscal year 2025.
- BioAtla, Inc. showed a decrease of -73.6% in Total Assets compared to the prior fiscal year.
- BioAtla, Inc. reported Cash and Equivalents of $7.12 million for fiscal year 2025.
- BioAtla, Inc. showed a decrease of -85.5% in Cash and Equivalents compared to the prior fiscal year.
- BioAtla, Inc. reported Stockholders Equity of -$36.19 million for fiscal year 2025.
- BioAtla, Inc. showed a decrease of -353.7% in Stockholders Equity compared to the prior fiscal year.
- BioAtla, Inc. reported R&D Expense of $43.57 million for fiscal year 2025.
- BioAtla, Inc. showed a decrease of -30.9% in R&D Expense compared to the prior fiscal year.
- BioAtla, Inc. reported Operating Income of -$59.30 million for fiscal year 2025.
- BioAtla, Inc. showed an increase of +19.8% in Operating Income compared to the prior fiscal year.
- BioAtla, Inc. reported Shares Outstanding of 63.46 million shares for fiscal year 2025.
- BioAtla, Inc. showed an increase of +9.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: